GSK shares dive as weaker sales and mounting costs unnerve investors
British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drug Business live – latest updates Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker vaccine sales, restructuring charges and its overall outlook. Britain’s second-biggest…
We haven't written up this one. Guardian Business has the full story — the link below goes straight to it.
